Shanghai Fosun Pharmaceutical (SHA:600196) controlled subsidiary Ningbo Fuying and other partners of the Nanjing Fund have agreed to reduce the fund's subscribed but unpaid capital contributions by 433.8 million yuan.
The group's share of the reduction is 266.5 million yuan, according to a Thursday filing with the Shanghai bourse.
Following the reduction, the Nanjing Fund's total subscribed capital will fall to 363.3 million yuan from 797.1 million yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.